Oncology has largely been immune to the reimbursement pressures that challenge virtually every other drug category. But that’s changing, and
read full article ›Manufacturers think CMS bars them from helping Medicare patients afford their medicines. This is incorrect. There are solutions...
read full article ›Diversity is now rightly a corporate priority in America. Companies large and small know that improving their diversity and inclusion policies will improve their culture and workforce. And Pharma is no different. Pharmas want more diverse representation in management, their boards, and in clinical trials. Should a similar lens be applied to access and reimbursement challenges – and in particular to patient support programs?
read full article ›This past year presented so many different challenges and obstacles that tested our strength and resiliency. The global pandemic forced
read full article ›Here we go again… on May 3rd Cvshealth released the CVS Caremark 2020 Drug Trend Report. One eye-catching stat was the
read full article ›The FDA’s accelerated approval process drives tremendous upside benefits for manufactures and patients through delivery of therapeutic innovations earlier than
read full article ›Express Scripts 2020 Update 2020 Drug Trend Report: specialty, rare & orphan, and cell & gene therapy management front and
read full article ›Do you know what employers are hearing, what they are looking for from payers, and how that will impact access
read full article ›An interesting look at the sources of copay assistance for privately insured patients (it’s not just manufacturers!). Also cited, nearly
read full article ›Manufacturers think CMS bars them from helping Medicare patients afford their medicines. This is incorrect. There are solutions which can help mitigate patient affordability challenges in Medicare. Join Real Endpoints webinar to understand the role patient support services can play in ensuring affordable access for Medicare beneficiaries.
read full article ›